NNVC Key Statistics, Chart & Performance
The current stock price of NNVC is 1.25 USD. In the past month the price decreased by -7.41%. In the past year, price decreased by -15.54%.
NNVC Latest News, Press Relases and Analysis
NNVC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About NNVC
Company Profile
NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 7 full-time employees. The company went IPO on 2004-08-12. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
Company Info
NANOVIRICIDES INC
1 Controls Drive
Shelton CONNECTICUT 06484 US
CEO: Anil Diwan
Employees: 7
Phone: 12036685580
NANOVIRICIDES INC / NNVC FAQ
What does NNVC do?
NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 7 full-time employees. The company went IPO on 2004-08-12. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
What is the stock price of NANOVIRICIDES INC today?
The current stock price of NNVC is 1.25 USD. The price decreased by -3.85% in the last trading session.
Does NNVC stock pay dividends?
NNVC does not pay a dividend.
What is the ChartMill rating of NANOVIRICIDES INC stock?
NNVC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists NNVC stock?
NNVC stock is listed on the NYSE Arca exchange.
What is the Price/Earnings (PE) ratio of NANOVIRICIDES INC (NNVC)?
NANOVIRICIDES INC (NNVC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).
Can you provide the ownership details for NNVC stock?
You can find the ownership structure of NANOVIRICIDES INC (NNVC) on the Ownership tab.
NNVC Technical Analysis
NNVC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NNVC. While NNVC seems to be doing ok healthwise, there are quite some concerns on its profitability.
NNVC Financial Highlights
Over the last trailing twelve months NNVC reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 32.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -97.23% | ||
| ROE | -113.25% | ||
| Debt/Equity | 0 |
NNVC Forecast & Estimates
7 analysts have analysed NNVC and the average price target is 7.14 USD. This implies a price increase of 471.2% is expected in the next year compared to the current price of 1.25.